In its Q1 report ending March 31, 2026, Heartflow demonstrated continued patient volume growth, with more than 219,000 patients assessed in 2025. The company leverages proprietary AI and computational fluid dynamics on CCTA scans to create detailed coronary artery models, positioning its Heartflow Platform as a differentiated solution in CAD diagnostics. While adoption remains below 2% penetration of the overall market opportunity, ongoing physician education and guideline endorsements support expansion. Key risks include reimbursement pressures, customer concentration, and an unresolved DOJ investigation related to compliance. Heartflow’s cash position and strong current ratio provide near-term liquidity for growth investments.